Volume 5.35 | Sep 5

Mammary Cell News 5.35 September 5, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Significance of PELP1/Histone Deacetylase 2/miR-200 Regulatory Network in EMT and Metastasis of Breast Cancer
Researchers showed that whole genome microRNAs (miR) array analysis using proline, glutamic acid and leucine rich protein 1 (PELP1)-overexpressing and PELP1-underexpressing model cells revealed that miR-200 and miR-141 levels inversely correlated with PELP1 expression. PELP1 knockdown significantly reduced tumor growth and metastasis compared with parental cells in an orthotopic xenograft tumor model. [Oncogene] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
PUBLICATIONS (Ranked by impact factor of the journal)

IBP Regulates Epithelial-to-Mesenchymal Transition and the Motility of Breast Cancer Cells via Rac1, RhoA and Cdc42 Signaling Pathways
Researchers found that increased expression of interferon regulatory factor 4 binding protein (IBP) was associated with the progression of breast cancer and that IBP levels were significantly elevated in matched distant metastases. [Oncogene] Full Article

Pre-Irradiation of Mouse Mammary Gland Stimulates Cancer Cell Migration and Development of Lung Metastases
Scientists demonstrated that pre-irradiation of the mammary gland increased by 1.8-fold the migration of cancer cells, by 2-fold the quantity of circulating cancer cells and by 2.4-fold the number of lung metastases. These adverse effects were shown to be associated with the induction of interleukin-6 and cyclooxygenase-2. [B J Cancer] Abstract

Altered Glucose Metabolism in Harvey-ras Transformed MCF10A Cells
Authors examined the effect Harvey-ras (H-ras) transformation on glucose metabolism using the untransformed MCF10A and H-ras oncogene transfected (MCF10A-ras) human breast epithelial cells, a model for early breast cancer progression. [Mol Carcinog] Abstract

Identification of FDA-Approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
Gene expression datasets of Cancer Stem Cells (CSCs) from six studies were subjected to connectivity map to identify drugs that may ameliorate gene expression patterns unique to CSCs. [Sci Rep] Full Article

Phospholipase D Inhibitor Enhances Radiosensitivity of Breast Cancer Cells
Researchers evaluated the effects of phospholipase D (PLD) inhibition on cell survival, cell death and DNA damage after exposure to ionizing radiation (IR). Combined IR treatment and PLD inhibition led to an increase in the radiation-induced apoptosis of MDA-MB-231 metastatic breast cancer cells. [Exp Mol Med] Full Article


Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
HER1-4 receptor and neuregulin-1 ligand mRNA expression levels in breast cancers and corresponding normal breast tissue from patients previously characterized for plasma and tissue estrogen levels were determined. [PLoS One] Full Article

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen Through Activation of Akt/mTOR Signaling
Researchers found that high ZNF703 expression mainly occurred in estrogen receptor-positive and progesterone receptor-positive breast cancers. Furthermore, 4-hydroxytamoxifen had different modes of action in breast cancer cell lines with high or low ZNF703 expression. [PLoS One] Full Article

Diagnostic and Therapeutic Strategy and the Most Efficient Prognostic Factors of Breast Malignant Fibrous Histiocytoma
Scientists analyzed the clinicopathological features of nine breast malignant fibrous histiocytoma patients. Of the five cases expressing Ki-67, two of three patients with axillary lymph node involvement died between 6-8 months, and two died at 17 and 26 months after diagnosis. The two remaining cases, with low Ki-67 expression, had no recurrent or metastatic disease at 145 months after diagnosis. [Sci Reps] Full Article

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
Genomic and Non-Genomic Actions of Progestogens in the Breast
The mechanism(s) by which progestogens might influence breast cancer risk appear to be mediated via genomic and/or non-genomic effects triggered by activated progestogen receptors. In this review, the authors describe the known genomic and non-genomic effects in the breast, especially focusing on the progestins. [J Steroid Biochem Mol Biol] Abstract

Breast Cancer Adaptive Resistance: HER2 and Cancer Stem Cell Repopulation in a Heterogeneous Tumor Society
The authors discuss the cancer stem cell-mediated tumor repopulation in acquired resistance of breast cancer in this review. [J Cancer Res Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Notre Dame and Moi University Join Research Efforts to Shed Light on Breast Cancer
A new joint research effort between the University of Notre Dame’s Eck Institute for Global Health and Harper Cancer Research Institute and a Kenyan doctoral student from Moi University is examining the unique manifestation of breast cancer in Kenya. [University of Notre Dame] Press Release

Irish Cancer Society Announces First Ever Cancer Research Collaboration of Its Kind
BREAST-PREDICT, which will see an investment by the Irish Cancer Society of €7.5 million over the next five years, is Ireland’s first Collaborative Cancer Research Centre which involves most of Ireland’s leading breast cancer researchers from a range of disciplines and a number of leading academic institutions. [Irish Cancer Society] Press Release

Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
Halozyme Therapeutics, Inc. announced that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin® (trastuzumab) for the treatment of HER2-positive breast cancer. [Halozyme, Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
Sequester Cuts May Delay Drug Approvals-And More
The United States Congress’s current mandatory budget cuts-sequestration-threaten unprecedented opportunities in all biomedical research and development. These severe cuts raise the particular concern that translation of intricate knowledge about the molecular biology of cancer to new, targeted treatments will be impeded in part by an underfunded U.S. Food and Drug Administration. [Sci Transl Med] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Breast Cancer, the Immune System and New Immunotherapeutic Opportunities
October 25, 2013
Milan, Italy

NEW The Translational Impact of Model Organisms in Cancer
November 5-8, 2013
San Diego, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Research Technician – Cancer Immunotherapy (The Netherlands Cancer Institute)

NEW Postdoctoral Position – Metastasis of Human Breast Cancer Subtypes (Weizmann Institute of Science)

NEW Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Senior Research Assistant/Postdoctoral Researcher- Tumor Biology/Molecular Imaging (RCSI Royal College of Surgeons in Ireland)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)

PhD Studentship – c-Met Pathway in Trastuzumab Resistant Breast Cancer (Barts Cancer Institute, Queen Mary University of London)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us